Bachem Holding (BANB) Aktievy
Bachem Holding AG, tillsammans med sina dotterbolag, tillhandahåller produkter för forskning, klinisk utveckling och kommersiell tillämpning till läkemedels- och bioteknikföretag över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 3/6 |
Belöningar
Riskanalys
Inga risker upptäckta för BANB från våra riskkontroller.
BANB Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Bachem Holding
69.0% undervärderad intrinsisk rabatt
Bachem Holding - The Purest Public Peptide Play?
View narrativeDE
Published 26 Apr
Bachem Holding AG Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | CHF 77.45 |
| 52 veckors högsta | CHF 83.25 |
| 52 veckors lägsta | CHF 48.52 |
| Beta | 0.80 |
| 1 månads förändring | 3.96% |
| 3 månaders förändring | 16.73% |
| 1 års förändring | 24.12% |
| 3 års förändring | 6.90% |
| 5 års förändring | -47.95% |
| Förändring sedan börsintroduktionen | 453.21% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Sep 07
BANB: New Manufacturing Partnership Will Raise Execution Risk And Limit Future Upside
The analyst price target for Bachem Holding has been adjusted from CHF 50.36 to CHF 52.40. Analysts point to updated fair value estimates, a revised discount rate, and refreshed assumptions for revenue growth, profit margins, and future P/E as the key drivers behind this change.
Uppdatering av berättelse • Jul 30
BANB: Future Execution At New Facility Is Expected To Sustain Fair Value
Analysts have raised their price target on Bachem Holding to CHF81.40 from CHF78.80, citing model updates that reflect slightly higher assumed revenue growth and profit margins, a modestly lower discount rate, and a small adjustment to the future P/E input. What's in the News for Bachem Holding Bachem Holding announced the next phase of its greenfield project in Sisslerfeld in Eiken, Switzerland, involving a large scale production facility with a total investment of more than CHF 500 million.Recent updates
Uppdatering av berättelse • Sep 07
BANB: New Manufacturing Partnership Will Raise Execution Risk And Limit Future Upside
The analyst price target for Bachem Holding has been adjusted from CHF 50.36 to CHF 52.40. Analysts point to updated fair value estimates, a revised discount rate, and refreshed assumptions for revenue growth, profit margins, and future P/E as the key drivers behind this change.Uppdatering av berättelse • Jul 30
BANB: Future Execution At New Facility Is Expected To Sustain Fair Value
Analysts have raised their price target on Bachem Holding to CHF81.40 from CHF78.80, citing model updates that reflect slightly higher assumed revenue growth and profit margins, a modestly lower discount rate, and a small adjustment to the future P/E input. What's in the News for Bachem Holding Bachem Holding announced the next phase of its greenfield project in Sisslerfeld in Eiken, Switzerland, involving a large scale production facility with a total investment of more than CHF 500 million.Uppdatering av berättelse • Jul 15
BANB: Rising Margin Expectations Will Increase Execution Risk And Restrain Upside
Analysts have raised their price target for Bachem Holding from CHF 46.00 to CHF 52.00, reflecting updated views that combine a slightly different discount rate, more cautious revenue growth assumptions, a higher projected profit margin, and a modestly lower future P/E multiple. What’s in the News for Bachem Holding ImmuPharma PLC appoints Bachem AG as manufacturing partner for the active pharmaceutical ingredient in its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for that project.Analysartikel • Jul 04
Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Uppdatering av berättelse • Jun 22
BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside
Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.
Uppdatering av berättelse • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.Uppdatering av berättelse • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.Uppdatering av berättelse • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
Ny berättelse • Apr 26
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Uppdatering av berättelse • Apr 16
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.Uppdatering av berättelse • Apr 02
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.Uppdatering av berättelse • Mar 19
BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential
Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.Uppdatering av berättelse • Mar 05
BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence
The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.Uppdatering av berättelse • Feb 18
BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views
Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.Uppdatering av berättelse • Feb 04
BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book
Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.Uppdatering av berättelse • Jan 21
BANB: Building K Execution Risks Will Limit Future Share Upside
Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.Uppdatering av berättelse • Jan 07
BANB: Building K Execution Risk Will Constrain Future Upside Potential
Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.Uppdatering av berättelse • Dec 14
BANB Building K Expansion Will Define Future Upside And Execution Risk
Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.Analysartikel • Dec 01
At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
While Bachem Holding AG ( VTX:BANB ) might not have the largest market cap around , it received a lot of attention from...Analysartikel • Oct 25
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...Uppdatering av berättelse • Sep 26
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.Analysartikel • Sep 18
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Ny berättelse • Mar 02
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.Aktieägarnas avkastning
| BANB | CH Life Sciences | CH Marknad | |
|---|---|---|---|
| 7D | 0.9% | -5.9% | -3.1% |
| 1Y | 24.1% | 0.8% | 11.3% |
Avkastning vs industri: BANB översteg Swiss Life Sciences branschen som gav 0.8 % under det senaste året.
Avkastning vs Marknaden: BANB översteg Swiss marknaden som gav 11.3 % under det senaste året.
Prisvolatilitet
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 5.4% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stabil aktiekurs: BANB har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Swiss.
Volatilitet över tid: BANB s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1971 | 2,725 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG, tillsammans med sina dotterbolag, tillhandahåller produkter för forskning, klinisk utveckling och kommersiell tillämpning till läkemedels- och bioteknikföretag över hela världen. Företaget är verksamt inom utveckling, produktion och regulatoriskt stöd av peptidbaserade aktiva farmaceutiska ingredienser, såsom peptid- och oligonukleotidbaserade nya kemiska substanser (NCE). Företaget erbjuder även kommersiella NCE:er och generika samt tjänster inom projektledning, kvalitet och reglering, analys, produktion enligt god tillverkningssed, produktion av forskningskvalitet samt leverans och vertikal integration.
Bachem Holding AG Sammanfattning av grunderna
| BANB grundläggande statistik | |
|---|---|
| Börsvärde | CHF 5.80b |
| Vinst(TTM) | CHF 148.96m |
| Intäkter(TTM) | CHF 708.53m |
39.0x
P/E-förhållande8.2x
P/S-förhållandeÄr BANB övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| BANB resultaträkning (TTM) | |
|---|---|
| Intäkter | CHF 708.53m |
| Kostnad för intäkter | CHF 517.20m |
| Bruttovinst | CHF 191.33m |
| Övriga kostnader | CHF 42.37m |
| Intäkter | CHF 148.96m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Mar 04, 2027
| Vinst per aktie (EPS) | 1.99 |
| Bruttomarginal | 27.00% |
| Nettovinstmarginal | 21.02% |
| Skuld/egenkapitalförhållande | 14.4% |
Hur har BANB utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
1.2%
Aktuell utdelningsavkastning45%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/09 07:39 |
| Aktiekurs vid dagens slut | 2026/09/09 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Bachem Holding AG bevakas av 17 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Laager | Berenberg |